MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS)
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
格式: | Conference item |
語言: | English |
出版: |
Elsevier
2022
|